EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, has no warnings or adverse events related to sexual ...

Investing.com -- Aytu BioPharma (NASDAQ:AYTU) stock gained 2.6% on Monday after the company announced the commercial availability of its newly approved depression treatment EXXUA in the United States.

DENVER - Aytu BioPharma, Inc. (NASDAQ:AYTU) announced Monday the commercial availability of EXXUA in the United States for the treatment of major depressive disorder (MDD). The small-cap biotech, with ...

EXXUA is now available through Aytu RxConnect pharmacies to ensure optimal access and availability EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving ...